Janean L. Fidel

Washington State University — United States

Medicine · Health Sciences

21h-index1.4kcitations73works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Veterinary Oncology Research(49), Virus-based gene therapy research(21), Sarcoma Diagnosis and Treatment(19), Cancer Research and Treatments(16), Infectious Diseases and Mycology(7)

Publications73 total

Treatment of feline oral squamous cell carcinoma with accelerated radiation and carboplatin with and without follow-up toceranib phosphate
Journal of Feline Medicine and Surgery·2025· 1 citedOpen Access
Update on development of monoclonal antibodies for use in clinical flow cytometry and research in dogs
Journal of Veterinary Diagnostic Investigation·2025Open Access
A pilot study investigating plasma pharmacokinetics and tolerance of oral capecitabine in carcinoma-bearing dogs
BMC Veterinary Research·2024· 1 citedOpen Access
Supplementary Figure 2 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs
2023Open Access
Supplementary Table 1 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs
2023Open Access
Supplementary Table 3 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs
2023Open Access
Supplementary Figure 1 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs
2023Open Access
Supplementary Table 1 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs
2023Open Access
Supplementary Figure 1 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs
2023Open Access
Data from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs
2023Open Access
Supplementary Table 2 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs
2023Open Access
Supplementary Table 4 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs
2023Open Access
Supplementary Table 3 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs
2023Open Access
Supplementary Table 2 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs
2023Open Access
Supplementary Table 4 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs
2023Open Access
Supplementary Figure 2 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs
2023Open Access
Data from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs
2023Open Access
Supplemental Figure Legends from Preclinical Validation of the Utility of BLZ-100 in Providing Fluorescence Contrast for Imaging Spontaneous Solid Tumors
2023Open Access
Supplemental Figure S1 from Preclinical Validation of the Utility of BLZ-100 in Providing Fluorescence Contrast for Imaging Spontaneous Solid Tumors
2023Open Access
Data from Preclinical Validation of the Utility of BLZ-100 in Providing Fluorescence Contrast for Imaging Spontaneous Solid Tumors
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Barbara Kaser‐Hotz(10), Rance K. Sellon(8), David M. Vail(7), Jeffrey N. Bryan(7), William C. Kisseberth(6), Corey Saba(6), Cheryl A. London(6), Katrina L. Mealey(5), Amy K. LeBlanc(5), Christina Mazcko(5), Aswini Cherukuri(5), Erika P. Berger(5), Megan E. Brown(5), Susan E. Lana(5), Kristen Weishaar(5), Brian K. Flesner(5), Jenna H. Burton(5), Jennifer L. Willcox(5), Anthony J. Mutsaers(5), J. Paul Woods(5)